Anthracycline dose intensification in adult acute lymphoblastic leukemia: Lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen

Deborah Thomas, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Elias Jabbour, Sherry Pierce, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

BACKGROUND: In previous studies of frontline therapy for adult acute lymphoblastic leukemia (ALL), early treatment with higher doses of anthracyclines has been reported to improve outcome. The current study was conducted to evaluate whether addition of anthracycline-based consolidation chemotherapy (Course 2) with liposomal daunorubicin (150 mg/m2 intravenously [IV] on Days 1 and 2) and cytarabine (1.5 g/m2 IV on Days 1 and 2) to the standard hyper-CVAD regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and cytarabine) would improve outcome. METHODS: Sixty-eight consecutive adults with de novo ALL or lymphoblastic lymphoma were treated with this modified hyper-CVAD regimen inclusive of rituximab for CD20 expression ≥20%. RESULTS: Sixty-three (93%) patients achieved complete response (CR). With a median follow-up of 90 months, the 5-year CR duration (CRD) and overall survival (OS) rates were 46% and 44%, respectively. Compared with 208 patients treated with standard hyper-CVAD (rates of 45% and 47%, respectively; P = not significant), outcome with the modified hyper-CVAD regimen was not improved overall. Outcome was improved by the addition of rituximab for the CD20-positive subset (rates of CRD and OS of 50% and 53%, respectively), whereas anthracycline intensification worsened outcome for the CD20-negative subset (rates of CRD and OS of 41% and 35%, respectively; P = .01) compared with standard hyper-CVAD. A high mortality rate related to infections in CR was noted among patients aged 60 years or older. CONCLUSIONS: In the context of the hyper-CVAD regimen, early anthracycline intensification did not improve outcome for adults with de novo ALL or lymphoblastic lymphoma.

Original languageEnglish (US)
Pages (from-to)4580-4589
Number of pages10
JournalCancer
Volume116
Issue number19
DOIs
StatePublished - Oct 1 2010
Externally publishedYes

Fingerprint

Anthracyclines
Vincristine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Doxorubicin
Cyclophosphamide
Dexamethasone
Cytarabine
Consolidation Chemotherapy
Daunorubicin
Survival
Methotrexate
Survival Rate
Mortality
Therapeutics
Infection
Rituximab

Keywords

  • Acute lymphoblastic leukemia
  • Anthracycline intensification
  • Hyper-CVAD regimen
  • Liposomal preparation of daunorubicin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Anthracycline dose intensification in adult acute lymphoblastic leukemia : Lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. / Thomas, Deborah; O'Brien, Susan; Faderl, Stefan; Ravandi, Farhad; Jabbour, Elias; Pierce, Sherry; Cortes, Jorge; Kantarjian, Hagop.

In: Cancer, Vol. 116, No. 19, 01.10.2010, p. 4580-4589.

Research output: Contribution to journalArticle

Thomas, Deborah ; O'Brien, Susan ; Faderl, Stefan ; Ravandi, Farhad ; Jabbour, Elias ; Pierce, Sherry ; Cortes, Jorge ; Kantarjian, Hagop. / Anthracycline dose intensification in adult acute lymphoblastic leukemia : Lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. In: Cancer. 2010 ; Vol. 116, No. 19. pp. 4580-4589.
@article{07909a8e5dc6406aa2e27771243bacd7,
title = "Anthracycline dose intensification in adult acute lymphoblastic leukemia: Lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen",
abstract = "BACKGROUND: In previous studies of frontline therapy for adult acute lymphoblastic leukemia (ALL), early treatment with higher doses of anthracyclines has been reported to improve outcome. The current study was conducted to evaluate whether addition of anthracycline-based consolidation chemotherapy (Course 2) with liposomal daunorubicin (150 mg/m2 intravenously [IV] on Days 1 and 2) and cytarabine (1.5 g/m2 IV on Days 1 and 2) to the standard hyper-CVAD regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and cytarabine) would improve outcome. METHODS: Sixty-eight consecutive adults with de novo ALL or lymphoblastic lymphoma were treated with this modified hyper-CVAD regimen inclusive of rituximab for CD20 expression ≥20{\%}. RESULTS: Sixty-three (93{\%}) patients achieved complete response (CR). With a median follow-up of 90 months, the 5-year CR duration (CRD) and overall survival (OS) rates were 46{\%} and 44{\%}, respectively. Compared with 208 patients treated with standard hyper-CVAD (rates of 45{\%} and 47{\%}, respectively; P = not significant), outcome with the modified hyper-CVAD regimen was not improved overall. Outcome was improved by the addition of rituximab for the CD20-positive subset (rates of CRD and OS of 50{\%} and 53{\%}, respectively), whereas anthracycline intensification worsened outcome for the CD20-negative subset (rates of CRD and OS of 41{\%} and 35{\%}, respectively; P = .01) compared with standard hyper-CVAD. A high mortality rate related to infections in CR was noted among patients aged 60 years or older. CONCLUSIONS: In the context of the hyper-CVAD regimen, early anthracycline intensification did not improve outcome for adults with de novo ALL or lymphoblastic lymphoma.",
keywords = "Acute lymphoblastic leukemia, Anthracycline intensification, Hyper-CVAD regimen, Liposomal preparation of daunorubicin",
author = "Deborah Thomas and Susan O'Brien and Stefan Faderl and Farhad Ravandi and Elias Jabbour and Sherry Pierce and Jorge Cortes and Hagop Kantarjian",
year = "2010",
month = "10",
day = "1",
doi = "10.1002/cncr.25319",
language = "English (US)",
volume = "116",
pages = "4580--4589",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "19",

}

TY - JOUR

T1 - Anthracycline dose intensification in adult acute lymphoblastic leukemia

T2 - Lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen

AU - Thomas, Deborah

AU - O'Brien, Susan

AU - Faderl, Stefan

AU - Ravandi, Farhad

AU - Jabbour, Elias

AU - Pierce, Sherry

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2010/10/1

Y1 - 2010/10/1

N2 - BACKGROUND: In previous studies of frontline therapy for adult acute lymphoblastic leukemia (ALL), early treatment with higher doses of anthracyclines has been reported to improve outcome. The current study was conducted to evaluate whether addition of anthracycline-based consolidation chemotherapy (Course 2) with liposomal daunorubicin (150 mg/m2 intravenously [IV] on Days 1 and 2) and cytarabine (1.5 g/m2 IV on Days 1 and 2) to the standard hyper-CVAD regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and cytarabine) would improve outcome. METHODS: Sixty-eight consecutive adults with de novo ALL or lymphoblastic lymphoma were treated with this modified hyper-CVAD regimen inclusive of rituximab for CD20 expression ≥20%. RESULTS: Sixty-three (93%) patients achieved complete response (CR). With a median follow-up of 90 months, the 5-year CR duration (CRD) and overall survival (OS) rates were 46% and 44%, respectively. Compared with 208 patients treated with standard hyper-CVAD (rates of 45% and 47%, respectively; P = not significant), outcome with the modified hyper-CVAD regimen was not improved overall. Outcome was improved by the addition of rituximab for the CD20-positive subset (rates of CRD and OS of 50% and 53%, respectively), whereas anthracycline intensification worsened outcome for the CD20-negative subset (rates of CRD and OS of 41% and 35%, respectively; P = .01) compared with standard hyper-CVAD. A high mortality rate related to infections in CR was noted among patients aged 60 years or older. CONCLUSIONS: In the context of the hyper-CVAD regimen, early anthracycline intensification did not improve outcome for adults with de novo ALL or lymphoblastic lymphoma.

AB - BACKGROUND: In previous studies of frontline therapy for adult acute lymphoblastic leukemia (ALL), early treatment with higher doses of anthracyclines has been reported to improve outcome. The current study was conducted to evaluate whether addition of anthracycline-based consolidation chemotherapy (Course 2) with liposomal daunorubicin (150 mg/m2 intravenously [IV] on Days 1 and 2) and cytarabine (1.5 g/m2 IV on Days 1 and 2) to the standard hyper-CVAD regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and cytarabine) would improve outcome. METHODS: Sixty-eight consecutive adults with de novo ALL or lymphoblastic lymphoma were treated with this modified hyper-CVAD regimen inclusive of rituximab for CD20 expression ≥20%. RESULTS: Sixty-three (93%) patients achieved complete response (CR). With a median follow-up of 90 months, the 5-year CR duration (CRD) and overall survival (OS) rates were 46% and 44%, respectively. Compared with 208 patients treated with standard hyper-CVAD (rates of 45% and 47%, respectively; P = not significant), outcome with the modified hyper-CVAD regimen was not improved overall. Outcome was improved by the addition of rituximab for the CD20-positive subset (rates of CRD and OS of 50% and 53%, respectively), whereas anthracycline intensification worsened outcome for the CD20-negative subset (rates of CRD and OS of 41% and 35%, respectively; P = .01) compared with standard hyper-CVAD. A high mortality rate related to infections in CR was noted among patients aged 60 years or older. CONCLUSIONS: In the context of the hyper-CVAD regimen, early anthracycline intensification did not improve outcome for adults with de novo ALL or lymphoblastic lymphoma.

KW - Acute lymphoblastic leukemia

KW - Anthracycline intensification

KW - Hyper-CVAD regimen

KW - Liposomal preparation of daunorubicin

UR - http://www.scopus.com/inward/record.url?scp=77957573172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957573172&partnerID=8YFLogxK

U2 - 10.1002/cncr.25319

DO - 10.1002/cncr.25319

M3 - Article

C2 - 20572037

AN - SCOPUS:77957573172

VL - 116

SP - 4580

EP - 4589

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 19

ER -